Laronde CEO Diego Miralles and Flagship general partner Avak Kahvejian

Big mon­ey: Flag­ship's uber-plat­form play Laronde rakes in $440M to chase pro­gram­ma­ble 'eR­NA'

With the suc­cess of Mod­er­na, par­ent com­pa­ny Flag­ship Pi­o­neer­ing has be­come the moth­er­ship for even more au­da­cious next-gen plat­form plays. In­vestors like what they see, and now they’ve opened the vault to a par­tic­u­lar­ly bold Flag­ship start­up work­ing on ring-shaped RNA it thinks could be the fu­ture of drug­mak­ing.

Laronde has closed a $440 mil­lion Se­ries B — one of the largest ever fundrais­ing rounds of its type — to pur­sue a pro­gram­ma­ble RNA plat­form the biotech has pre­vi­ous­ly said could churn out 100 mar­ket­ed drugs or drug pro­grams in 10 years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.